Found: 13
Select item for more details and to access through your institution.
Risk Factors for Eribulin-induced Severe Neutropenia in Patients With Recurrent Breast Cancer.
- Published in:
- In Vivo, 2024, v. 38, n. 1, p. 500, doi. 10.21873/invivo.13466
- By:
- Publication type:
- Article
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 167, n. 1, p. 81, doi. 10.1007/s10549-017-4489-9
- By:
- Publication type:
- Article
Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 144, n. 2, p. 249, doi. 10.1007/s10549-014-2867-0
- By:
- Publication type:
- Article
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00584-5
- By:
- Publication type:
- Article
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
- Published in:
- Cancer Science, 2014, v. 105, n. 1, p. 81, doi. 10.1111/cas.12302
- By:
- Publication type:
- Article
Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
- Published in:
- Breast Cancer (13406868), 2024, v. 31, n. 6, p. 1167, doi. 10.1007/s12282-024-01614-1
- By:
- Publication type:
- Article
Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 497, doi. 10.1007/s12282-023-01442-9
- By:
- Publication type:
- Article
Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
- Published in:
- Breast Cancer (13406868), 2022, v. 29, n. 5, p. 808, doi. 10.1007/s12282-022-01360-2
- By:
- Publication type:
- Article
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
- Published in:
- Breast Cancer (13406868), 2018, v. 25, n. 1, p. 34, doi. 10.1007/s12282-017-0781-0
- By:
- Publication type:
- Article
Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
- Published in:
- Breast Cancer (13406868), 2016, v. 23, n. 4, p. 617, doi. 10.1007/s12282-015-0612-0
- By:
- Publication type:
- Article
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
- Published in:
- Breast Cancer (13406868), 2015, v. 22, n. 2, p. 185, doi. 10.1007/s12282-013-0474-2
- By:
- Publication type:
- Article